Trial Profile

To Evaluate Safety and Efficacy of SCT-I10A Combined SCT200 or SCT-I10A Combined SCT200 Plus Chemotherapy in Advanced Esophageal Squamous Cell Carcinoma and Colorectal Cancer: a Phase Ⅰb, Open-label, Multicenter Study

Status: Not yet recruiting

Phase of Trial: Phase I

Latest Information Update: 10 Feb 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Finotonlimab (Primary) ; SCT 200 (Primary) ; Capecitabine; Oxaliplatin
Indications Carcinoma; Colorectal cancer; Oesophageal cancer; Squamous cell cancer
Focus Adverse reactions
Sponsors Sinocelltech

20 Jan 2020 New trial record
15 Jan 2020 Planned End Date changed from 1 Dec 2021 to 1 Dec 2022.
15 Jan 2020 Planned primary completion date changed from 1 Aug 2021 to 1 Aug 2022.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com